Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)Retained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming (PHAR) Receivables (2019 - 2024)

Historic Receivables for Pharming (PHAR) over the last 6 years, with Q4 2024 value amounting to $56.4 million.

  • Pharming's Receivables rose 1680.23% to $56.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $56.4 million, marking a year-over-year increase of 1680.23%. This contributed to the annual value of $56.4 million for FY2024, which is 1680.23% up from last year.
  • According to the latest figures from Q4 2024, Pharming's Receivables is $56.4 million, which was up 1680.23% from $48.3 million recorded in Q4 2023.
  • Pharming's Receivables' 5-year high stood at $56.4 million during Q4 2024, with a 5-year trough of $28.7 million in Q4 2022.
  • Its 5-year average for Receivables is $40.6 million, with a median of $37.1 million in 2020.
  • Per our database at Business Quant, Pharming's Receivables crashed by 1280.39% in 2021 and then skyrocketed by 6809.23% in 2023.
  • Quarter analysis of 5 years shows Pharming's Receivables stood at $37.1 million in 2020, then dropped by 12.8% to $32.3 million in 2021, then dropped by 11.16% to $28.7 million in 2022, then skyrocketed by 68.09% to $48.3 million in 2023, then rose by 16.8% to $56.4 million in 2024.
  • Its Receivables was $56.4 million in Q4 2024, compared to $48.3 million in Q4 2023 and $28.7 million in Q4 2022.